Wirkstoffe & Arzneimittelsicherheit

Gegenanzeigen · Eliquis

Eliquis 2.5 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 6

HOS-124369 · Präparat HOS-095863

• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. • Active clinically significant bleeding. • Hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 5.2). • Lesion or condition if considered a significant risk factor for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities. • Concomitant treatment with any other anticoagulant agent e.g., unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, rivaroxaban, dabigatran etexilate, etc.) except under specific circumstances of switching anticoagulant therapy (see section 4.2), when UFH is given at doses necessary to maintain an open central venous or arterial catheter or when UFH is given during catheter ablation for atrial fibrillation (see sections 4.4 and 4.5).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fondaparinux (HOS-110096) heparin (HOS-086930) rivaroxaban (HOS-086236) enoxaparin (HOS-118623) dabigatran etexilate (HOS-086233) dalteparin (HOS-118624) warfarin (HOS-085950)